These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32652877)

  • 1. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
    Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
    J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
    Mei Y; Liao X; Zhu L; Yang H
    J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
    Yang L; Tian Y; Leong WS; Song H; Yang W; Wang M; Wang X; Kong J; Shan B; Song Z
    Breast Cancer Res; 2018 Sep; 20(1):113. PubMed ID: 30227879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
    Wang R; Zhang T; Yang Z; Jiang C; Seng J
    J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
    Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
    Chang L; Hu Z; Zhou Z; Zhang H
    Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells.
    Kim H; Park GS; Lee JE; Kim JH
    Br J Cancer; 2013 Jul; 109(2):351-9. PubMed ID: 23799854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.
    Chen Y; Tang W; Zhu X; Zhang L; Zhu Y; Xiao H; Xu J; Fang Y; Li X; Tang C; Shi J
    Bioengineered; 2021 Dec; 12(2):11506-11519. PubMed ID: 34905470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
    Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
    Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Potentiates Cell Apoptosis and Drug Sensitivity to Taxanes and Adriamycin in Breast Cancer.
    Yu J; Jin T; Zhang T
    Med Sci Monit; 2020 Jul; 26():e922672. PubMed ID: 32623440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
    Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
    J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
    Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
    Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PA-MSHA inhibits the growth of doxorubicin-resistant MCF-7/ADR human breast cancer cells by downregulating Nrf2/p62.
    Wei Y; Liu D; Jin X; Gao P; Wang Q; Zhang J; Zhang N
    Cancer Med; 2016 Dec; 5(12):3520-3531. PubMed ID: 27758045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
    Zang H; Li Y; Zhang X; Huang G
    Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
    Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
    Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.